AMRN Key Stats
| Income Statement | |
| Revenue TTM | 0.00 |
| Revenue Quarterly YoY Growth | |
| EPS Diluted TTM | -0.5203 |
| EPS Diluted Quarterly YoY Growth | |
| Net Income TTM | -179.18M |
| Profitability | |
| Gross Profit Margin Quarterly | |
| Profit Margin Quarterly | |
| Dividend | |
| Dividend Yield | 0.00% |
| Payout Ratio TTM Pro | Go Pro |
| Current Valuation | |
| Market Cap | 1.064B |
| Enterprise Value | 1.035B |
| PE Ratio TTM | |
| PE 10 Pro | Go Pro |
| PEG Ratio | |
| Price / Book Value | |
| Other | |
| Beta Pro | Go Pro |
| Debt to Equity Ratio | |
| Free Cash Flow | -55.98M |
| Return on Equity | |
AMRN News
- Vascepa Data Should Make Amarin Longs Worried May 20
- Amarin: It's The Strategy, Not The Science May 20
- Amarin's (AMRN) Vascepa Not in FDA Orange Book for April Street Insider May 17
- AMARIN CORP PLC\UK Financials May 17
- A Disconnect Between Future Prospects of Drug Candidates Versus Where Share Pric... May 16
- 7 Biotechnology Stocks to Sell Now Investor Place May 15
- Amarin & Celsion: Post-Earnings Roundup May 15
- Amarin (AMRN) Sees Early Gains; Stock up 4% Street Insider May 14
- Amarin Reports Solid Vascepa TRx Growth, Stock Holds Its Ground May 13
- Weekly Stock Watch - Week Of May 13, 2013 May 11
AMRN Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Amarin Corporation is down 29.89% over the last year vs S&P 500 Total Return up 31.59%, Achillion Pharmaceuticals up 16.23%, and Omthera Pharmaceuticals down 3.25%.
AMRN Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Cash Flow Statement View Statement
You may also be interested in these AMRN related companies
Pro Ratings for AMRN
Pro Report PDF for AMRN
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.
Download AMRN Pro Report PDF
Pro Strategies Featuring AMRN
Did Amarin Corporation make it into our Pro Portfolio Strategies?
AMRN Profile
Exchange: NASDAQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Amarin Corporation plc is a clinical-stage biopharmaceutical company with expertise in lipid science focused on the treatment of cardiovascular disease. The Company's lead product candidate is AMR101 (icosapent ethyl). The firm has completed two pivotal Phase 3 studies of AMR101 which include Marine and Anchor under the Special Protocol Assessment agreements with the U.S. Food and Drug Administration. The company was founded on March 1, 1989 and is headquartered in Dublin, Ireland.
Other AMRN Resources
- Company Website
- Investor Relations
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| AMRN | 7.06 | -0.08 | -1.12% | 1.064B |
